Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled…

Overview of attention for article published in Cardiovascular Diabetology, March 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (78th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

blogs: 1 blog

twitter: 4 X users

Citations

dimensions_citation: 69 Dimensions

Readers on

mendeley: 181 Mendeley

Summary Blogs X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 10,896 followers.

CARMELINA（トラゼンタ）EASD10月4日発表済（Unpublished） https://t.co/J5Bt9vSLn6 https://t.co/FZ3DyYz6Ea https://t.co/FzRPtiRHtN EWTOPIA75（ゼチーア）AHA　Late Breaking Clinical Trial　11月10日（Unpublished） https://t.co/TyDO6C4PTc

18 Oct 2018

Reply Repost Favourite

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio

13 Jul 2018

Reply Repost Favourite

Estudio CARMELINA, ya nos están contando lo bien diseñado que está y el alto riesgo de enfermedad renal de los pacientes incluidos... ¿Anticipando resultados mediocres? Pronto lo veremos https://t.co/mxlu5vXazJ

26 Mar 2018

Reply Repost Favourite

CARMELINA trial methods and baseline characteristics nearly 7000 patients with diabetes, 74% have eGFR<60 mL/min or macroalbuminuria. This will be an important trial @VladoPerkovic https://t.co/KDZxiSXxnG

20 Mar 2018

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.